Your browser doesn't support javascript.
loading
Synthetic routes and clinical application of new drugs approved by EMA during 2023.
Xia, Yu; Chen, Qingqing; Liu, He-Nan; Chi, Yuan; Zhu, Ying; Shan, Li-Shen; Dai, Bing; Wu, Lin; Shi, Xiaobao.
Afiliação
  • Xia Y; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Chen Q; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Liu HN; Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Chi Y; Department of Radiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
  • Zhu Y; Department of Neurology, The First Hospital of China Medical University, Shenyang, China.
  • Shan LS; Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
  • Dai B; Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: daib@sj-hospital.org.
  • Wu L; Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: cmuwulin8681@163.com.
  • Shi X; Department of Radiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China. Electronic address: xiaobao13up@163.com.
Eur J Med Chem ; 277: 116762, 2024 Nov 05.
Article em En | MEDLINE | ID: mdl-39151275
ABSTRACT
In 2023, the European Medicines Agency (EMA) granted approval to 77 new molecular entities (NMEs), consisting of 45 new chemical entities (NCEs) and 32 new biological entities (NBEs). These pharmacological agents encompass a broad spectrum of therapeutic domains, including oncology, cardiology, dermatology, diagnostic medicine, endocrinology, gastroenterology and hepatology, metabolic disorders, and neurology. Among the 77 approved pharmaceuticals, three received accelerated review status, and 17 (22 %) were granted orphan drug designation for the treatment of rare diseases. This review provides an overview of the clinical applications and synthetic routes of 42 newly approved NCEs by the EMA in 2023. The objective is to offer a comprehensive understanding of the synthetic approaches used in the development of these drug molecules, thereby inspiring the creation of novel, efficient, and applicable synthetic methodologies.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprovação de Drogas Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur J Med Chem Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprovação de Drogas Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur J Med Chem Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: França